Cystatin-C Clinical Survey

Thank you for helping us evaluate the potential benefits of adding Cystatin C testing to the list of insured medical tests in Ontario.
 
Cystatin C is a small molecule that is freely filtered by the kidney and has minimal secretion or reabsorption. It is generated at a constant rate, is not affected by diet or muscle mass, and is more strongly associated with risk for cardiovascular events and all-cause mortality. Cystatin C can be used independently or in conjunction with serum Creatinine as a marker for estimating kidney function (eGFR) and has key advantages for certain patient groups including those of African descent and extremes of muscle mass.

You have been invited to take part in this survey because you ordered a Creatinine test for at least one patient between April 2021 and August 2021. You would have received Cystatin C test results in addition to your Creatinine test results as part of a New Tests and Technology Fund pilot through the Ontario Ministry of Health.

Please contact cystatinc@alphalabs.ca or visit https://alphalabs.ca/CystatinC for more information.

  • You will receive a $50 honorarium for completing this 10 minute survey.
  • Your survey responses will be used in anonymized format only, and you will not be asked to provide any patient personal health information.
  • A valid e-mail address is required for survey participation. Any contact information provided will be used for the optional follow-up purposes you specify at the end of this survey (e.g., honoraria payment, update on findings).

Question Title

* 1. Do you consent to Alpha Labs using your survey answers for:
a. Reporting on the clinical use of Creatinine and Cystatin C test results, and
b. To inform policies and decisions related to Ontario Health Insurance Plan (OHIP) coverage and practice recommendations?

0 of 24 answered
 

T